Asacol 800mg Mr Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Asacol 800mg MR tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 800 mg of mesalazine (active substance) and 152.75 mg of lactose monohydrate (excipient).
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Modified ReleaseTablets
Red-brown, oblong tablets marked ‘WC 800’.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Ulcerative colitis: For the treatment of mild to moderate acute exacerbations. For the maintenance of remission.
Crohn’s ileo-colitis: For the maintenance of remission.
4.2 Posology and method of administration
Swallow whole with water. Do not break, crush or chew the tablets before swallowing.
ADULTS:
Mild acute exacerbations of ulcerative colitis: Three tablets (2.4g) a day in divided doses.
Moderate acute exacerbations of ulcerative colitis: Six tablets (4.8g) a day in divided doses.
Maintenance of remission of ulcerative colitis: Up to three tablets (2.4g) a day once daily or in divided doses.
Maintenance of remission of Crohn’s ileocolitis: Up to three tablets (2.4g) a day in divided doses.
ELDERLY: The normal adult dosage may be used unless renal function is impaired (see section 4.4).
CHILDREN: Not recommended.
4.3 Contraindications
A history of sensitivity to salicylates or renal sensitivity to sulfasalazine. Confirmed severe renal impairment (GFR less than 20 ml/min). Hypersensitivity to any of the ingredients. Severe hepatic impairment. Gastric or duodenal ulcer, haemorrhagic tendency.
4.4 Special warnings and precautions for use
Geriatric Use
Use in the elderly should be cautious and subject to patients having normal renal function
Intolerance
Discontinue treatment immediately if acute symptoms of intolerance occur including vomiting, abdominal pain or rash. This medicine contains lactose. Patients with the rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine because of the presence of lactose monohydrate.
Mesalazine inhibits the thiopurine methyl-transferase (TPMT) activity in vitro and may therefore impair the metabolism of azathioprine and 6-mercaptopurine. Standard haematological indices (including the white cell count) should be monitored repeatedly in patients taking azathioprine, especially at the beginning of such combination therapy, whether or not mesalazine is prescribed.
Renal disorder
Mesalazine is excreted rapidly by the kidney, mainly as its metabolite, N-acetyl-5-aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Asacol should be used with extreme caution in patients with confirmed mild to moderate renal impairment (see section 4.3). Patients on mesalazine should have renal function monitored, (with serum creatinine levels measured) prior to treatment start. Renal function should then be monitored periodically during treatment, for example every 3 months for the first year, then every 6 months for the next 4 years and annually thereafter, based on individual patient history. Physicians should take into account risk factors such as prior and concomitant medications, duration and severity of disease and concurrent illnesses. Treatment with mesalazine should be discontinued if renal function deteriorates. If dehydration develops, normal electrolyte and fluid balance should be restored as soon as possible.
Blood Dyscrasias
Serious blood dyscrasias (some with fatal outcome) have been reported very rarely with mesalazine. Haematological investigations including a complete blood count may be performed prior to initiation and whilst on therapy according to the physician’s judgement. Such tests should be done immediately if the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat. Treatment should be stopped if there is suspicion or evidence of blood dyscrasia.
4.5 Interaction with other medicinal products and other forms of interaction
‘Asacol’ tablets should not be given with lactulose or similar preparations, which lower stool pH and may prevent release of mesalazine.
Concurrent use of other known nephrotoxic agents, such as NSAIDs and azathioprine, may increase the risk of renal reactions (see section 4.4).
4.6 Fertility, Pregnancy and lactation
Pregnancy
Mesalazine is known to cross the placental barrier, but the limited data available on its use in pregnant women do not allow accurate assessment of possible adverse effects.
Mesalazine should therefore be used with caution during pregnancy and lactation when the potential benefit outweighs the possible hazards in the opinion of the physician.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Lactation
Low concentrations of mesalazine and higher concentrations of its N-acetyl metabolite have been detected in human milk. While the clinical significance of this has not been determined, caution should be exercised when mesalazine is administered to a nursing woman. Hypersensitivity reactions like diarrhoea cannot be excluded. Therefore, if the suckling neonate develops suspected adverse reactions consideration should be given to discontinuation of breast-feeding or discontinuation of treatment of the mother.
4.7 Effects on ability to drive and use machines
No influence.
4.8 Undesirable effects
In Phase III clinical studies in patients with moderate active ulcerative colitis, treated for 6 weeks with either 2.4g/day or 4.8g/day, there was no difference in the adverse event profiles between doses. The events are presented in the table below:
|
Adverse Events Reported in > 2% o: |
? Patients in Either Treatment Group | |||
|
Adverse Event* |
Asacol 800 mg (4.8 g/day) |
Mesalazine 400 mg (2.4 g/day) | ||
|
N |
= 213 (%) |
N |
= 235 (%) | |
|
Headache |
16 |
(7.5%) |
14 |
(6.0%) |
|
Abdominal pain |
9 |
(4.2%) |
12 |
(5.1%) |
|
Diarrhoea |
8 |
(3.8%) |
9 |
(3.8%) |
|
Nausea |
8 |
(3.8%) |
4 |
(1.7%) |
|
Respiratory infection |
7 |
(3.3%) |
4 |
(1.7%) |
|
Exacerbation of colitis |
6 |
(2.8%) |
6 |
(2.6%) |
|
Dyspepsia |
6 |
(2.8%) |
5 |
(2.1%) |
|
Vomiting |
6 |
(2.8%) |
2 |
(0.9%) |
|
Flatulence |
5 |
(2.3%) |
7 |
(3.0%) |
|
Rectal disorder |
4 |
(1.9%) |
6 |
(2.6%) |
|
Flu syndrome |
3 |
(1.4%) |
8 |
(3.4%) |
|
Rash |
3 |
(1.4%) |
5 |
(2.1%) |
|
Increased cough |
1 |
(0.5%) |
9 |
(3.8%) |
|
Sinusitis |
1 |
(0.5%) |
5 |
(2.1%) |
|
Rhinitis |
0 |
(0.0%) |
7 |
(3.0%) |
*Adverse events are listed by decreasing frequency as observed in the 4.8 g/day
treatment group
Adverse events seen with oral mesalazine products are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal pain. Headache and arthralgia/myalgia have also been reported.
Blood and lymphatic system disorders:
Rare (<1/1,000): leucopenia, neutropenia, agranulocytosis, aplastic anaemia and thrombocytopenia.
Cardiac disorders:
Rare (<1/1,000): myocarditis, pericarditis Nervous disorders:
Common (>1/100 to <1/10): headache
Rare (<1/1,000): peripheral neuropathy, vertigo
Respiratory, thoracic and mediastinal disorders:
Rare (<1/1,000): bronchospasm, eosinophilic pneumonia Very rare (<1/10,000): interstitial pneumonitis
Gastrointestinal disorders:
Common (>1/100 to <1/10): nausea, vomiting, diarrhoea, abdominal pain Rare (<1/1,000): pancreatitis
Very rare(<1/10,000): exacerbation of the symptoms of colitis Hepato-biliary disorders:
Rare (<1/1,000): abnormalities of hepatic function / abnormal liver function test, hepatitis
Skin and subcutaneous tissue disorders:
Rare (<1/1,000): alopecia, lupus erythematosus-like reactions, rash (including urticaria), bullous skin reactions,
Very rare(<1/10,000): Stevens Johnson syndrome, erythema multiforme Musculo-skeletal:
Common (>1/100 to <1/10: arthralgia/myalgia Renal and urinary disorders
Rare (<1/1,000): interstitial nephritis and nephrotic syndrome with oral mesalazine treatment, usually reversible on withdrawal. Renal failure has been reported. Mesalazine-induced nephrotoxicity should be suspected in patients developing renal dysfunction during treatment.
General disorders and administration site conditions Rare (<1/1,000): Drug fever Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
There is no clinical experience with overdose of Asacol 800 mg. Mesalazine is not metabolized to salicylate. There is no specific antidote for mesalazine overdose and treatment is symptomatic and supportive. It may include intravenous infusion of appropriate electrolytes.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
ATC code: A07EC02
Mesalazine is thought to have a topical anti-inflammatory effect on the intestinal mucosa, where it has been shown to inhibit prostaglandin and leukotriene synthesis, release of reactive oxygen species and other actions.
Moderately active ulcerative colitis:
Two active-controlled trials enrolled a total of 687 patients comparing Asacol 4.8 g/day (800 mg formulation) with mesalazine enteric coated tablets 2.4 g/day (400 mg formulation) in patients with mildly to moderately active ulcerative colitis. Both studies were of six weeks duration. Treatment success was defined on the basis of the Physician’s Global Assessment (PGA), which took into consideration clinical assessments of rectal bleeding, stool frequency, and the patient’s functional assessment and sigmoidoscopic examination. Across the two studies 4.8 g/day provided superior efficacy in patients with moderately active disease.
In the first study a total of 301 patients with mildly to moderately active UC were enrolled. Of these, 169 patients with moderately active disease were assessed for efficacy in a pre-defined subgroup analysis. In these patients, 4.8 g/day gave greater treatment success than 2.4 g/day (72% treatment success compared with 57%).
In the second study a total of 386 patients with mildly to moderately active ulcerative colitis were randomly assigned to treatment. In the 254 patients with moderately active disease, the pre-defined primary efficacy analysis showed that 4.8 g/day gave greater treatment success than 2.4 g/day (72% treatment success compared to 59%).
In both studies, more patients showed improvement on 4.8 g/day compared to 2.4 g/day across the clinical assessments (stool frequency, rectal bleeding, sigmoidoscopy and PGA). In combined studies, 4.8 g/day showed statistically significant superiority in the sigmoidoscopy and PGA scores.
At Week 3, more patients with moderately active disease achieved treatment success on 4.8 g/day compared with 2.4 g/day in each study and in the combined analysis (62% vs. 53%). These differences were not statistically significant.
In combined studies among patients with moderately active disease, the efficacy benefit of 4.8 g/day over 2.4 g/day was consistent across various subgroups including age, gender, race, ulcerative colitis disease history, prior medication usage and extent of disease (proctitis, proctosigmoiditis, left-sided colitis and pancolitis).
5.2 Pharmacokinetic properties
Asacol 800mg MR tablets are coated with an acrylic-based resin. Tablets coated with this specific resin have been shown to delay release of mesalazine until it reaches the terminal ileum and beyond.
Based on cumulative urinary recovery of 5-aminosalicylic acid and its metabolite, N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA) from single dose studies in healthy volunteers, approximately 20% of the orally administered mesalazine in Asacol 800mg MR tablets is systemically absorbed, leaving the remainder available for local action and elimination in the faeces. The absorbed mesalazine is rapidly acetylated in the gut mucosal wall and by the liver to N-Ac-5-ASA which is excreted mainly by the kidney.
The extent of systemic exposure to mesalazine, based on AUC and Ae%, following oral administration of Asacol 800mg MR tablets, is similar in fasted and fed subjects.
Pharmacokinetics studies for Asacol 800mg MR tablets indicated that the tmax for mesalazine and its metabolite, N-Ac-5-ASA, is prolonged, reflecting the modified release characteristics, and ranged from 4 to 12 hours. Large intersubject variability in the plasma concentrations and terminal exponential half-lives (t1/2) of mesalazine and N-Ac-5-ASA is seen following administration of Asacol 800mg MR tablets. The mean (t 1 /2) for mesalazine and N-Ac-5-ASA are usually about 12 hours, but may vary from 2 to 15 hours.
In patients with mildly to moderately active ulcerative colitis who participated in clinical safety and efficacy studies, the mean plasma concentrations of mesalazine and N-Ac-5-ASA following oral administration of 4.8g/day with the Asacol 800mg MR tablet for 6 weeks (N = 273) were 1931 ng/mL and 2951 ng/mL, respectively. In these studies, the mean plasma concentrations of mesalazine and N-Ac-5-ASA were 967 ng/mL and 1789 ng/mL, respectively, in patients with mildly to moderately active ulcerative colitis who were orally administered 2.4g/day with a mesalazine 400mg modified release tablet for 6 weeks (N = 275). The systemic exposure to mesalazine and N-Ac-5-ASA in patients with moderately active UC is similar to that observed in patients with mildly active UC.
5.3 Preclinical safety data
Apart from effects on the kidney (see section 4.4), preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction. The latter was studied in rats and rabbits at oral doses up to 480 mg/kg/day and no evidence was detected for teratogenic effects or foetal toxicity due to mesalazine.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Core lactose monohydrate
sodium starch glycolate talc
povidone
magnesium stearate colloidal anhydrous silica
Coating methacrylic acid - methyl methacrylate copolymer (1:2) talc
dibutyl sebacate ferric oxide red (E172)
methacrylic acid - methyl methacrylate copolymer (1:1)
ferric oxide yellow (E172)
macrogol
Black ink containing propylene glycol
ferric oxide black (E172) ammonium hydroxide ethanol
shellac glaze (bleached, de-waxed)
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions. Keep the bottle tightly closed.
6.5 Nature and contents of container
HDPE oblong bottle with a child-resistant closure, cotton, and silica gel desiccant pouches. Pack-sizes of 12, 36 or 180 tablets.
HDPE round bottle with a child-resistant closure, cotton, and silica gel desiccant pouches. Pack-size of 84 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7
MARKETING AUTHORISATION HOLDER
Allergan Pharmaceuticals International Limited
Clonshaugh Industrial Estate
Coolock
Dublin 17
Ireland
8
9
10
22/03/2016